Proteomic Profiling of Pre- and Post-Surgery Saliva of Glioblastoma Patients: A Pilot Investigation DOI Open Access
Alexandra Muntiu, Fabiana Moresi, Federica Vincenzoni

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(23), P. 12984 - 12984

Published: Dec. 3, 2024

Glioblastoma multiforme (GBM) is an extremely aggressive brain tumor characterized by a high infiltration capability and recurrence rate. Early diagnosis crucial to improve the prognosis personalize therapeutic approach. This research explored, LC-MS proteomic analysis after proteolytic digestion, molecular profile of pre- post-operative saliva pools from newly diagnosed (ND) GBM patients comparing different times collection (R). CYCS, PRDX2, RAB1C, PSMB1, KLK6, TMOD3, PAI2, PLBD1, CAST, AHNAK, all involved in processes invasiveness chemo- radio-resistance, were found depict pre-surgery both ND R GBM. PADI4 CRYAB proteins, identified among most abundant proteins exclusive classified as elevated glioma, could have potential role disease biomarkers. Selected panels S100 potentially differentiate patient saliva. TPD52 IGKV3, exclusively saliva, be additionally distinctive relapse. Among pools, label-free relative quantitation showed statistically significant levels TXN, SERPINB5, FABP5, S100A11 between pools. All these higher ND_ R_T0 with respect CTRL modulation surgery or chemo-radiotherapy combined treatment, suggesting panel predictive prognostic These results highlight confirm that biofluid featured for easily accessible low collection, promising source biomarkers, showing new opportunities development targeted therapies diagnostic tools.

Language: Английский

Proteomic Profiling of Pre- and Post-Surgery Saliva of Glioblastoma Patients: A Pilot Investigation DOI Open Access
Alexandra Muntiu, Fabiana Moresi, Federica Vincenzoni

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(23), P. 12984 - 12984

Published: Dec. 3, 2024

Glioblastoma multiforme (GBM) is an extremely aggressive brain tumor characterized by a high infiltration capability and recurrence rate. Early diagnosis crucial to improve the prognosis personalize therapeutic approach. This research explored, LC-MS proteomic analysis after proteolytic digestion, molecular profile of pre- post-operative saliva pools from newly diagnosed (ND) GBM patients comparing different times collection (R). CYCS, PRDX2, RAB1C, PSMB1, KLK6, TMOD3, PAI2, PLBD1, CAST, AHNAK, all involved in processes invasiveness chemo- radio-resistance, were found depict pre-surgery both ND R GBM. PADI4 CRYAB proteins, identified among most abundant proteins exclusive classified as elevated glioma, could have potential role disease biomarkers. Selected panels S100 potentially differentiate patient saliva. TPD52 IGKV3, exclusively saliva, be additionally distinctive relapse. Among pools, label-free relative quantitation showed statistically significant levels TXN, SERPINB5, FABP5, S100A11 between pools. All these higher ND_ R_T0 with respect CTRL modulation surgery or chemo-radiotherapy combined treatment, suggesting panel predictive prognostic These results highlight confirm that biofluid featured for easily accessible low collection, promising source biomarkers, showing new opportunities development targeted therapies diagnostic tools.

Language: Английский

Citations

0